|
211 |
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
Enthalten in BMC cancer Bd. 20, 11.11.2020, Nr. 1, date:12.2020: 1-13
|
|
|
|
212 |
How often does office hysteroscopy reveal pathology not previously noted on transvaginal ultrasound—a look at two typical reproductive endocrinology patient groups, including failed IVF–ET patients
Enthalten in Gynecological surgery Bd. 7, 31.3.2010, Nr. 4, date:11.2010: 417-421
|
|
|
|
213 |
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study
Enthalten in BMC cancer Bd. 19, 21.6.2019, Nr. 1, date:12.2019: 1-9
|
|
|
|
214 |
Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial
Enthalten in BMC cancer Bd. 13, 15.10.2013, Nr. 1, date:12.2013: 1-9
|
|
|
|
215 |
Klinische Endpunkte in Real-World-Register-Studien
Enthalten in Der Onkologe Bd. 26, 28.4.2020, Nr. 6, date:6.2020: 530-541
|
|
|
|
216 |
Komplikationsmanagement in der Brustchirurgie
Enthalten in Der Gynäkologe Bd. 49, 18.12.2015, Nr. 3, date:3.2016: 180-184
|
|
|
|
217 |
LEFTY2 inhibits endometrial receptivity by downregulating Orai1 expression and store-operated Ca2+ entry
Enthalten in Journal of molecular medicine Bd. 96, 11.12.2017, Nr. 2, date:2.2018: 173-182
|
|
|
|
218 |
Mammotome® versus ATEC®: a comparison of two breast vacuum biopsy techniques under sonographic guidance
Enthalten in Archives of gynecology and obstetrics Bd. 281, 30.4.2009, Nr. 2, date:2.2010: 287-292
|
|
|
|
219 |
Measurement of tumour size with mammography, sonography and magnetic resonance imaging as compared to histological tumour size in primary breast cancer
Enthalten in BMC cancer Bd. 13, 5.7.2013, Nr. 1, date:12.2013: 1-8
|
|
|
|
220 |
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy
Enthalten in BMC cancer Bd. 8, 26.2.2008, Nr. 1, date:12.2008: 1-10
|
|
Administration
